GS
The Goldman Sachs Group, Inc.
GS's fundamentals are strong: revenue grew 19% and its operating margin rose 4 points to 40%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MDBH
MDB Capital Holdings, LLC Class A common
There isn't enough reported data to score MDBH yet.
GS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| N/A | |
| N/A |
GS's revenue and profitability are currently strong. Free cash flow and net leverage aren't meaningful measures for financial services companies like GS.
MDBH Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| N/A | |
| N/A |
MDBH's profitability is currently weak. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like MDBH.
GS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.6x | $528 | -42% |
| Current | 13x | $914 | — |
| Forward | 13x | $914 | — |
| Fair | 14x | $940 | +2.9% |
| Expensive | 17x | $1,214 | +33% |
Historical ranges are pointers, not guarantees.
GS's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MDBH PE Valuation
MDBH has no meaningful PE right now: it lost money over the past year.
GS Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GS, with profitability improving. However, they disagree widely on these estimates.
MDBH Forward outlook
There aren't enough analyst estimates for MDBH to show an outlook.
GS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $72.35 | +4% |
| Q3 2026 | $69.58 | +41% |
| Q2 2026 | $64.82 | +43% |
| Q1 2026 | $54.75 | +27% |
| Q4 2025 | $51.32 | +27% |
| Q3 2025 | $49.22 | +44% |
| Q2 2025 | $45.37 | +45% |
| Q1 2025 | $43.08 | +68% |
| Q4 2024 | $40.54 | +77% |
GS has the edge over MDBH on earnings quality, reporting a profit while its opponent remains loss making.
MDBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$4.03 | -553% |
| Q1 2026 | -$3.14 | -349% |
| Q4 2025 | -$2.57 | -325% |
| Q3 2025 | $0.81 | +$3.48 |
| Q2 2025 | $0.89 | +$3.43 |
| Q1 2025 | $1.26 | +$2.89 |
| Q4 2024 | $1.14 | +$2.21 |
| Q3 2024 | -$2.67 | -$2.14 |
MDBH has swung to a loss: it lost $4.03 per share over the past year, after a profit the year before.
GS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.7B | +23% |
| Q2 2026 | $20.3B | +39% |
| Q1 2026 | $17.2B | +14% |
| Q4 2025 | $13.5B | -3% |
| Q3 2025 | $15.2B | +20% |
| Q2 2025 | $14.6B | +15% |
| Q1 2025 | $15.1B | +6% |
| Q4 2024 | $13.9B | +23% |
GS's revenue is growing: $18.7B last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +2 points |
| Q2 2026 | 42% | +8.1 points |
| Q1 2026 | 38% | +0.2 points |
| Q4 2025 | 44% | +5.6 points |
| Q3 2025 | 36% | +4.1 points |
| Q2 2025 | 34% | +3.2 points |
| Q1 2025 | 37% | +0.6 points |
| Q4 2024 | 38% | +18 points |
GS's operating margin was 37% last quarter, up 2 points from the same quarter a year ago.
MDBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $2.1M | +134% |
MDBH has the edge over GS in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -134% | +612 points |
| Q4 2024 | -746% | N/A |
| Q4 2022 | -81% | N/A |
GS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +72% |
| Q2 2026 | $5.6B | +7.8% |
| Q1 2026 | -$32.4B | +$5.3B |
| Q4 2025 | -$16.8B | -136% |
| Q3 2025 | $2.1B | +$40.6B |
| Q2 2025 | $5.2B | -6.8% |
| Q1 2025 | -$37.7B | -$9.2B |
| Q4 2024 | $46.2B | +$75.1B |
MDBH has the stronger cash trend. Its trailing FCF is up 14% versus its history, compared with GS at down 278%.
MDBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.4M | -699% |
| Q4 2024 | $229.3K | +$2.4M |
| Q3 2024 | -$2.1M | -$377.2K |
| Q1 2024 | -$2.4M | -$1.2M |
| Q4 2023 | -$2.1M | -$1.3M |
| Q3 2023 | -$1.7M | +$671.1K |
| Q1 2023 | -$1.2M | +$135.2K |
| Q4 2022 | -$813.6K | +$4.3M |
MDBH's free cash flow was −$7M over the past year, against −$11M the year before. Free cash flow isn't a meaningful measure for financial services companies like MDBH.
GS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -5.4x | Net Cash |
| Q2 2026 | -6.1x | Net Cash |
| Q1 2026 | -6.7x | Net Cash |
| Q4 2025 | -6.4x | Net Cash |
| Q3 2025 | -3.5x | Net Cash |
| Q2 2025 | -3.1x | Net Cash |
| Q1 2025 | -3.9x | Net Cash |
| Q4 2024 | -4.7x | Net Cash |
GS has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like GS.
MDBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.7x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
MDBH has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like MDBH.
GS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.5 | Neutral |
| Stochastic | 16.3 | Oversold |
GS's weekly RSI is 45 (neutral) and its Stochastic is 16 (oversold).
MDBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 30.6 | Neutral |
MDBH's weekly RSI is 36 (neutral) and its Stochastic is 31 (neutral).
GS PE vs Financial Services Sector
| Metric | GS | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 0.8% above |
| PE % | 46 | 63 | 17 pts below |
GS is trading at 13x earnings, in line with the Financial Services sector's median of 13x, though its earnings don't support one.
MDBH PE vs Financial Services Sector
| Metric | MDBH | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
MDBH has no meaningful PE right now: it lost money over the past year.
GS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $895.5 | 2% above |
| 20 week MA | $977.4 | 6.5% below |
| 50 week MA | $945.4 | 3.4% below |
| 100 week MA | $804.5 | 14% above |
| 200 week MA | $602.7 | 52% above |
GS has stronger trend alignment. GS is above 3 of 5 weekly averages versus MDBH above 0 of 4.
MDBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.94 | 2.1% below |
| 20 week MA | $2.59 | 27% below |
| 50 week MA | $3.03 | 37% below |
| 100 week MA | $3.90 | 51% below |
MDBH is in a downtrend: it's below all four of its weekly moving averages, and 51% below its 100-week average.
GS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $230.7 | $256.2 | +11% |
| 2021 | $256.2 | $385.0 | +50% |
| 2022 | $385.0 | $345.5 | -10% |
| 2023 | $345.5 | $385.8 | +12% |
| 2024 | $385.8 | $576.2 | +49% |
| 2025 | $576.2 | $907.0 | +57% |
| 2026 YTD | $907.0 | $913.6 | +0.7% |
GS has the edge over MDBH on returns for 2026, with the stronger performance.
MDBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $10.5 | $11.5 | +9.8% |
| 2024 | $11.5 | $6.89 | -40% |
| 2025 | $6.89 | $3.50 | -49% |
| 2026 YTD | $3.50 | $1.90 | -46% |
MDBH has finished lower in two of the last three years. It's down 46% so far in 2026.